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The estrogen receptor (ER) α is overexpressed in most breast cancers, and its level 
serves as a major prognostic factor. It is important to develop quantitative molecular 
imaging methods that specifically detect ER in vivo and assess its function throughout 
the entire primary breast cancer and in metastatic breast cancer lesions. This study 
presents the biochemical and molecular features, as well as the magnetic resonance 
imaging (MRI) effects of two novel ER-targeted contrast agents (CAs), based on pyri-
dine-tetra-acetate-Gd(III) chelate conjugated to 17β-estradiol (EPTA-Gd) or to tamoxifen 
(TPTA-Gd). The experiments were conducted in solution, in human breast cancer cells, 
and in severe combined immunodeficient mice implanted with transfected ER-positive 
and ER-negative MDA-MB-231 human breast cancer xenografts. Binding studies with 
ER in solution and in human breast cancer cells indicated affinities in the micromolar 
range of both CAs. Biochemical and molecular studies in breast cancer cell cultures 
showed that both CAs exhibit estrogen-like agonistic activity, enhancing cell proliferation, 
as well as upregulating cMyc oncogene and downregulating ER expression levels. The 
MRI longitudinal relaxivity was significantly augmented by EPTA-Gd in ER-positive cells 
as compared to ER-negative cells. Dynamic contrast-enhanced studies with EPTA-Gd 
in vivo indicated specific augmentation of the MRI water signal in the ER-positive versus 
ER-negative xenografts, confirming EPTA-Gd-specific interaction with ER. In contrast, 
TPTA-Gd did not show increased enhancement in ER-positive tumors and did not 
appear to interact in vivo with the tumors’ ER. However, TPTA-Gd was found to interact 
strongly with muscle tissue, enhancing muscle signal intensity in a mechanism indepen-
dent of the presence of ER. The specificity of EPTA-Gd interaction with ER in vivo was 
further verified by acute and chronic competition with tamoxifen. The chronic tamoxifen 
treatment also revealed that this drug increases the microvascular permeability of breast 
cancer xenograft in an ER-independent manner. In conclusion, EPTA-Gd has been 
shown to serve as an efficient molecular imaging probe for specific assessment of breast 
cancer ER in vivo.
Keywords: estrogen receptor-targeted probes, contrast agents for Mri, breast cancer, estrogen receptor, 
molecular imaging
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inTrODUcTiOn
Breast cancer is the most common malignancy in women and 
the second leading cause of cancer death among women (1). 
The overexpression of the estrogen receptor (ER) (2) is currently 
an established molecular feature for assessing breast cancer 
prognosis and predicting response to endocrine therapies [Ref. 
(3) and references cited therein]. The critical importance of ER 
measurements in managing breast cancer treatment was recently 
emphasized in the results of a meta-analysis of randomized trials 
showing that ER status of the primary tumor was the only patient 
or tumor characteristic that strongly predicted tamoxifen efficacy, 
whereas the progesterone receptor measurement did not seem to 
be importantly predictive of efficacy (4).
Estrogen receptor status is predominantly evaluated today 
by immunohistochemistry staining of ER, which is a semi-
quantitative method and, therefore, may lack reproducibility and 
standardization across different laboratories (5–8). In addition, 
this method requires fresh randomly selected tumor tissue, not 
always available, particularly in metastatic breast disease.
Part of the above described limitations can be overcome by 
developing molecular imaging techniques that will detect and 
map ER level over the entire tumor tissue in a quantitative man-
ner. Thus, ER imaging has become an important target for future 
development (9). Today, molecular imaging of ER is primarily 
based on the application of radiolabeling selective estrogen recep-
tor modulators (SERMs) that can be detected by single photon 
emission computed tomography (SPECT) or positron emission 
tomography (PET) (10). The most clinically advanced ER imag-
ing method today uses 16-α-[f-18]-fluoro-17-β-estradiol (FES) 
and PET (11). These methods provided quantitative imaging ER 
expression in vivo in animal models and in breast cancer patients 
(12–14), but it is not applicable yet as a routine imaging technique 
for the workup of breast cancer patients.
Currently, magnetic resonance imaging (MRI) methods 
demonstrated excellent efficiency for breast cancer detection and 
diagnosis [Ref. (15) and references cited therein]. The challenge 
of molecular MRI to evaluate ER expression can provide a direct 
critical prognostic factor at the stage of diagnosis. Therefore, we 
embarked on developing novel contrast agents (CAs) targeted to 
the ER that should be detected by MRI. To that end, we have 
synthesized two new CAs targeted to the ER, which are composed 
of Gadolinium chelate of pyridine-tetra-acetate (PTA-Gd) con-
jugated with the native ligand 17β-estradiol (EPTA-Gd) or with 
the antiestrogen tamoxifen (TPTA-Gd), and evaluated their MRI 
properties in solution, in breast cancer cells and in breast cancer 
xenografts in animal models (16–18). In addition, direct struc-
tural information on the crystal structure of the ligand-binding 
domain of ER bound to the europium chelate of EPTA (EPTA-Eu) 
was obtained using X-ray crystallography (19). This paper pre-
sents characterization of the binding capacity and the hormonal/
molecular effects of EPTA-Gd and TPTA-Gd in human breast 
cancer cells, as well as restates and expands the data evaluation 
of the MRI properties of these CAs in cell cultures and animal 
models of breast cancer. We have focused on investigating the 
interaction and binding affinity with ER, the hormonal-induced 
changes in cell proliferation, and the up or downregulation of 
estrogen-induced genes. Furthermore, investigation of the 
ER-specific and non-specific interactions of these probes in breast 
cancer cells and tumors and in muscle tissue, as well as the com-
petition with tamoxifen emphasized the advantage of EPTA-Gd 
over TPTA-Gd as an ER-targeted CA in vivo.
MaTerials anD MeThODs
solution-Binding affinity to er
The binding affinities were measured by a radioactive inhibitory 
competitive assay in solution, using recombinant hERα (1.76 nM) 
(PanVera, Inc., Madison, WI, USA), tritiated 17β-estradiol 
(3HE2 = 2.0–3.5 nM, 140 Ci/mmol) (NEN, Boston, MA, USA), and 
EPTA-Gd and TPTA-Gd as the competing ligands. Experiments 
were done in duplicates. The concentration of competing ligand 
required to replace half of the tritiated 17β-estradiol that would 
be bound to the hERα, IC50, was derived by non-linear regres-
sion analysis of the experimental data to the following equation:
 
Y =
+ −( ) +
Non-Specific Binding
Total Binding Specific Binding 1/ 1  logIC50 0log X−( )  
with Y, the observed data and X, the inhibitor concentration; non-
specific binding of 3HE2 is measured by competition with excess 
of 1 μM cold E2 and total-specific binding is maximal binding 
of 3HE2 measured without competition. The absolute inhibition 
constant, Ki, was determined according to the Cheng–Prusoff 
equation:
 Ki IC5 1 HE2 Kd
3= 0 /[ ( / )]+  
using Kd = 0.2 nM of 17β-estradiol.
cells
T47D (clone 11) and MDA-MB-231 human breast cancer cells 
were cultured in RPMI 1640 medium supplemented with 10% 
FCS (Biological Industries, Israel), 4  mM l-glutamine, and 
0.1% combined antibiotics (Bio-Lab, Israel). In addition, T47D 
medium included insulin (0.8 ml/l) and MDA medium included 
pyruvate (1 mM). MCF7 human breast cancer cells were cultured 
in DMEM medium supplemented with 6% FCS (Biological 
Industries, Israel), 4 mM l-glutamine, and 0.1% combined anti-
biotics (Bio-Lab, Israel).
Estrogen receptor-positive MDA-MB-231 cells were obtained 
by stably transfecting the wild type (WT) MDA-MB-231 cells 
with a plasmid encoding tetracycline repressor (TR) protein 
pcDNA6/TR (T-REX™ System, Invitrogen, USA) and with a 
plasmid encoding ERα pcDNA4/ER, as previously described 
(20). The expression of ERα in these cells was induced by adding 
doxycycline (1 μg/ml) (doxycycline hyclate, Sigma-Aldrich, MO, 
USA) to the growth medium for at least 3 days.
cell Proliferation assay
Cells were grown in phenol red-free medium supplemented with 
10% dextran-coated charcoal stripped fetal bovine serum – DCC-
FBS (Biological industries, Beit Haemek, Israel) for a minimum 
of 5 days and were then seeded in a 96-well plate (3.5 × 103 cells/
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well) and cultured in the same medium with the various treat-
ments administered to the medium. The number of cells was 
determined by the cell viability MTT (3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyl tetrazolium bromide) assay (21). Each data 
point presents an average of six-replicate wells in a single experi-
ment; experiments were repeated several times as indicated in 
the text.
Western Blotting
Estrogen receptor α, cMyc, and α-tubulin protein levels were 
determined using immunoblotting with mouse anti-human ERα 
antibody (clone 6F11, Novocastra Laboratories, UK), mouse 
anti-human cMyc antibody (9e10, Abcam, MA, USA), and 
mouse anti-human α-tubulin antibody (clone DM-1A, Sigma-
Aldrich, MO, USA), respectively. Goat anti-mouse horseradish 
peroxidase and alkaline phosphatase were used as secondary 
antibodies (Jackson ImmunoResearch Laboratories, PA, USA). 
Densitometric analyses were performed using Quantity One 4.6 
(Bio-Rad Laboratories, CA, USA). The changes in the expression 
due to treatment with the ER-targeted probes were performed in 
cells grown in phenol red-free medium for a minimum of 5 days 
prior to the treatment. The expression of ER in the different 
human breast cancer cell lines was quantified by normalizing the 
intensity of the bands to those of standard, known concentrations 
of recombinant hERα protein (PanVera, Inc., Madison, WI, USA).
Mri- and Fluorescence-Binding studies
The interaction of the ER-targeted probes with ER-positive 
and ER-negative MDA-MB-231 cells were investigated by 
T1-relaxation measurements and by a fluorescence assay using 
the Eu-chelate of EPTA, EPTA-Eu. Studies were also performed on 
cells cultivated on microspheres. The cells, ~3 × 106, were seeded 
on 0.5  ml microspheres (Biosilon polystyrene microspheres, 
NUNC, 160–300 μm diameter) placed in non-adherent bacterial 
Petri dishes using FCS-supplemented DMEM medium. After 
4  days, the medium was replaced by phenol red-free medium 
supplemented with DCC-FBS for additional 3 days. On day 7, the 
medium was replaced by serum-free medium containing either 
EPTA-Gd or TPTA-Gd for 60 min incubation and placed in wells 
(0.5  ml/well) (Microtest 96-well plate, BD Falcon, NJ, USA). 
Proton T1-relaxation rates were measured at 23°C with a 4.7-T 
Bruker Biospec spectrometer (Bruker, Karlsruhe, Germany) by 
applying a 2D spin-echo pulse sequence, field of view (FOV) 
8 cm × 8 cm, matrix of 256 × 192, slice thickness of 3 mm, echo 
time (TE) =  16  ms, and six different repetition times (TRs). 
T1-relaxation times per pixel were calculated by non-linear 
least-squares fitting (using simplex algorithm Matlab R2009b, 
MathWorks, Natick, MA, USA) of the MRI signal intensity, SI, to 
the equation SI = So[1 − exp(−TR/T1)] with two free parameters 
So and T1.
T1- and T2-relaxation rate measurements were also conducted 
in ER-positive and ER-negative cells cultured on microspheres 
and perfused during the experiments under sterile conditions 
with oxygenated, phenol red-free, and serum-free medium at 
36 ± 1°C, as previously described (22). The measurements were 
conducted in a 9.4-T NMR spectrometer (DMX-400, Bruker, 
Karlsruhe, Germany). EPTA-Gd and TPTA-Gd were gradually 
added at various concentrations (range 0.1–7.5  μM) to the 
perfusion medium reservoir and at the end of the experiments, 
the CA was washed out by fresh medium. Proton T1-relaxation 
rates (R1) and T2-relaxation rates (R2) were measured by MRS 
of the water signal using standard inversion recovery pulse 
sequence and a Car–Purcell–Meiboom–Gill sequence, respec-
tively. ΔR1 and ΔR2 were defined as the difference between R1 
(or R2) of cells perfused with medium containing the CA and 
the contrast-free medium. T1 relaxivity, r1, in mM−1  s−1, was 
calculated from the slope of a linear fit of ΔR1 as a function of 
the CA concentration.
For the fluorescence-binding assay, both ER-positive and 
ER-negative cells were seeded and grown on polystyrene Biosilon 
beads, as described above, placed in glass Petri dishes covered 
with silicone (Sigmacote, Sigma-Aldrich, MO, USA) to minimize 
non-specific binding. On day 7, the medium was replaced with 
fresh serum-free medium containing EPTA-Eu at concentrations 
ranging from 0.1 to 0.5 μM for 60 min at 37°C. Then, the cells were 
washed three times with 10 ml of the fresh medium, and DELFIA 
enhancement solution (1244-105, PerkinElmer, MA, USA) was 
added (4–5 ml/plate) and stirred in the dark for 15 min at room 
temperature. The solution was then transferred into a 48-well 
plate (300  μl/well in quadruplicate) and scanned on a Wallac 
Victor3 instrument, using the standard europium time resolved 
fluorescence measurement (340 nm excitation, 400 μs delay, and 
emission collection for 400 μs at 615 nm). The specific binding 
to ER was calculated by subtracting the non-specific fluorescence 
of ER-negative cells from the fluorescence of ER-positive cells. 
The fluorescence optical density (OD) intensities were converted 
to molar units by using a calibration curve obtained from OD 
values of known EPTA-Eu concentrations. The final concentra-
tion data points reflecting specific binding in the cells to ER were 
fitted to a one-site binding equation Y = Bmax × X/(Kd + X), 
where Y is the measured OD converted to molar units and X is 
the administrated concentration of EPTA-Eu using non-linear 
least-squares Levenberg–Marquardt algorithm (origin version 
6.1) yielding the dissociation constant Kd, which is the inverse 
of the association constant Ka and maximal-binding capacity 
(Bmax) of EPTA-Eu to ER.
Mri of Breast cancer Xenografts in Mice
All experimental protocols were reviewed and approved by the 
Institutional Animal Care and Use Committee of the Weizmann 
Institute of Science. Female CB-17 severe combined immunode-
ficient (SCID) mice (Harlan Biotech Israel Ltd., Israel), 6–7 weeks 
old, were ovariectomized. About a week later, WT human 
MDA-MB-231 breast cancer cells and stable ER-transfected 
MDA-MB-231 cells were inoculated (2.5 × 106 cells in 0.1 ml phos-
phate-buffered saline) into the left and right mammary fat pad, 
respectively. One week later, ER expression in the implanted cells 
was induced by supplementing the drinking water with 0.2 mg/
ml doxycyclin (44577 doxycycline hyclate, Sigma-Aldrich, MO, 
USA) in 3% sucrose. The size of the xenografts was measured by 
caliper, estimating the volume by assuming a hemielipsoid shape 
according to volume = (length/2 × width/2 × height/2) × 4π/3.
In vivo MRI experiments were conducted 2–4 weeks after cell 
implantation. During the MRI scanning, mice were anesthetized 
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with isoflurane (Medeva Pharmaceuticals, Inc., Bethlehem, PA, 
USA) (3% for induction and 1–2% for maintenance) mixed with 
compressed air (1  l/min) and delivered through a nasal mask. 
Once anesthetized, the animals were placed in a head-holder to 
assure reproducible positioning inside the magnet. Respiration 
rate was monitored and kept throughout the scanning period 
around 60–80 breaths per minute.
All in  vivo MR images were acquired on a 9.4-T Biospec 
AVANCE II spectrometer (Bruker, Karlsruhe, Germany). The 
protocol included a multi-slice T2-weighted sequence and a 
dynamic contrast-enhanced (DCE) 3D gradient-echo pulse 
sequence with TE/TR 2.5/15 ms and flip angle 40°, four averages 
(1.5  min). The latter images alternated between images of the 
tumors recorded in the axial direction with a spatial resolution of 
0.156 mm × 0.156 mm × 1.2 mm and images of the descending 
aorta and muscle tissue in coronal direction with spatial resolu-
tion of 0.234 mm × 0.156 mm × 1 mm.
Each ER-targeted probe was injected as a bolus into the tail 
vein of the mice. The dose of EPTA-Gd was 0.03 mmol/kg (n = 4) 
or 0.075 mmol (n = 5). The dose of TPTA-Gd was 0.075 mmol/
kg (n = 4).
Competition of EPTA-Gd with tamoxifen was tested in vivo 
using two modes of tamoxifen treatment, acute (1 h) and chronic 
(3  days). In the acute treatment, tamoxifen citrate salt  –  TAM 
(T9262, Sigma-Aldrich, St. Louis, MO, USA) dissolved in sterile 
sunflower oil (4 mg/ml) or 4-hydroxytamoxifen – OHT (H7904, 
Sigma-Aldrich) dissolved in sterile sunflower oil containing 
20% ethanol were stirred overnight at 37°C and administered by 
intraperitoneal injection at a final dose of 0.07  mmol/kg TAM 
(n = 3) or 0.1 mmol/kg OHT (n = 1). One hour later, EPTA-Gd 
was injected into the tail vein at a dose of 0.075 mmol/kg. In the 
chronic treatment, tamoxifen pellets (5  mg/pellet, 4w-release 
time; Innovative Research of America, Sarasota, FL, USA) were 
implanted subcutaneously in the back of the mouse and 3 days 
later ETPA-Gd was administered (n = 4). The MRI protocol was 
the same as described above for the direct, non-competitive, 
contrast-enhanced experiments.
Changes in signal intensity were calculated per pixel yielding 
enhancement datasets defined as [I(t)−I(0)]/I(0), where I(0) and 
I(t) are the signal intensities pre- and post-contrast, respectively. 
Enhancement maps at pixel resolution were calculated in regions 
of interest (ROI) in all slices including tumors’ tissue. ROIs were 
delineated on the anatomical T2-weighted images and transferred 
to the corresponding DCE images. I(0) per pixel was calculated as 
a mean intensity of the four pre-contrast images.
histology
The tumors were removed, fixed in 4% formaldehyde, sectioned 
to 4  μm histological slices and stained with hematoxylin and 
eosin (H&E), as well as immune-stained for nuclear ERα. The 
immunostaining was performed using rabbit monoclonal anti-
ER antibody (ER-SP1, Ventana Medical System, AZ, USA) and 
an automated slide staining BenchMark XT system operated, 
according to the manufacturer’s instructions (Ventana Medical 
System, AZ, USA). An experienced breast pathologist evaluated 
the extent of intensity of staining [absent (i = 0), weak (i = +1), 
moderate (i = +2), or strong (i = +3)], and the percentage of 
ER-stained cell nuclei. These two evaluations were used for cal-
culating a specific intensity index defined as: ΣI (i) × fraction of 
cells stained with (i).
statistics
Student’s two-tailed paired t-tests (GraphPad Software, Inc., 
QuickCalcs Web site http://www.graphpad.com/quickcalcs/
ttest1.cfm) were applied to evaluate the effect of each treatment 
on the measured cellular parameter relative to control non-
treated cells or to control ER-negative cells undergoing the same 
treatment. This test was also applied to evaluate the differences 
between the size and EPTA-Gd-induced enhancement in the 
ER-positive and ER-negative xenografts. A level at p < 0.05 was 
considered significant.
resUlTs
Binding to er in solution and in cells
The chemical structures of the two gadolinium chelate of pyr-
idine-tetra-acetate (PTA-Gd) conjugated with the native ligand 
17β-estradiol (EPTA-Gd) or with the antiestrogen tamoxifen 
(TPTA-Gd) are presented in Figure  1A. The binding affinities 
of EPTA-Gd and TPTA-Gd to an isolated hERα were deter-
mined in reference to tamoxifen by a competitive radioactive-
binding assay with 3HE2 as described in Section “Materials 
and Methods” (Figure  1B). Non-linear least-squares fitting of 
the experimental data yielded inhibitory dissociation constants 
KiEPTA-Gd = 0.97 ± 0.07 μM and KiTPTA-Gd = 0.13 ± 0.006 μM as 
compared to KiTamoxifen = 0.005 ± 0.001 μM.
Specific binding of these agents to ER in human breast cancer 
cells was demonstrated by augmentation in the T1-relaxation 
rate in ER-positive cells as compared to ER-negative cells culti-
vated on microspheres. The change in T1-relaxation rate in the 
ER-positive cells in the presence of EPTA-Gd (6 μM), measured 
in eight independent experiments, yielded a mean  ±  SD of 
74 ± 20 ms−1. This change in T1-relaxation rate was significantly 
higher than that in ER-negative cells of 46 ± 20 ms−1 (p = 0.02, 
n = 8). Nine independent experiments with TPTA-Gd (5 μM) 
augmented the T1-relaxation rate in ER-positive cells by 
a mean  ±  SD of 72  ±  6  ms−1 and in ER-negative cells by 
64 ±  10  ms−1 with a borderline significant difference between 
the cells (p = 0.07, n = 9).
Concentration-dependent studies of the T1-relaxation rates 
(R1) of ER-positive and ER-negative breast cancer cells cultivated 
on microspheres and perfused during the experiments with 
increasing concentrations of each CA indicated an increase in 
T1 relaxivity due to binding to ER (Figures 2A,B). The concen-
tration dependence of ΔR1 (the difference between R1 of cells 
perfused with medium containing the CA and the same cells 
perfused with contrast-free medium) showed that EPTA-Gd 
and TPTA-Gd augment the T1 relaxivity in ER-positive cells 
as compared to ER-negative cells by 45 and 22%, respectively. 
After washing out EPTA-Gd (7.5 μM) or TPTA-Gd (7.5 μM) 
from the perfusion system with fresh medium, both ΔR1 
and ΔR2 remained significantly higher in ER-positive cells as 
compared to ER-negative cells. Generally, gadolinium-based 
FigUre 2 | T1 and T2 measurements with ePTa-gd and TPTa-gd in perfused er-positive and er-negative MDa-MB-231 human breast cancer cells. 
ΔR1 and ΔR2 are defined as the difference between R1 (or R2) of cells perfused with medium containing the contrast agent and R1 (or R2) of these cells perfused 
with contrast-free medium. (a) T1 relaxivity of EPTA-Gd in ER-positive and negative cells: r1 (ER-positive) = 28.5 ± 0.1 mM−1s−1 (n = 2) and r1 (ER-
negative) = 19.6 mM−1s−1. (B) T1 relaxivity measurements of TPTA-Gd in ER-positive and negative cells: r1 (ER-positive) = 42.1 mM−1s−1 and r1 (ER-
negative) = 36 mM−1s−1. The cells were perfused in the NMR tube and treated with increasing concentrations of each contrast agent. T1-relaxation time of water 
protons was determined at 9.4 T using inversion recovery pulse sequence. Different symbols for ER-positive cells in (a) represent two independent experiments. r1 
relaxivities were calculated as the slope of the linear fit to the data as explained in the text. (c) Change in T1-relaxation rates, ΔR1, in the perfused cells after 
washing out EPTA-Gd (7.5 μM) or TPTA-Gd (7.5 μM) from the perfusion system with fresh medium. (D) Change in T2-relaxation rates, ΔR2, in the perfused cells as 
in (c). Data presented in (c,D) are mean ± SD of three to six measurements recorded 30–60 min after the beginning of the washout process.
FigUre 1 | The chemical structure of 17β-estradiol pyridine-tetra-acetate-gd (ePTa-gd) and tamoxifen pyridine-tetra-acetate-gd (TPTa-gd) (a) and 
their competitive displacement curves by tritiated 17β-estradiol (3he2) on a human recombinant erα in reference to tamoxifen competition (B).
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CAs will affect both T1- and T2-relaxation rates and thus the 
results above confirm specific binding of these agents to ER 
(Figures 2C,D).
Further verification of the binding to ER was performed by 
direct measurement of the binding affinity of cellular ER to the 
europium complex of EPTA-Eu, using a dissociation-enhanced 
lanthanide fluorescence assay. Specific binding to ER was obtained 
by subtracting the non-specific binding in ER-negative cells from 
the total binding in ER-positive cells (Figure  3). The specific 
binding curve (Figure 3B) yielded an association constant in the 
FigUre 4 | erα expression in various human breast cancer cell lines. 
(a) Western blots of recombinant hERα and of ERα in human breast cancer 
cell extracts. (B) Quantification of western blot experiments (n = 2).
FigUre 3 | Binding affinity of ePTa-eu to er in human breast cancer cells. ER-positive and ER-negative MDA-MB-231 human breast cancer cells, grown on 
microspheres, were incubated in the presence of the indicated concentrations of EPTA-Eu for 1 h at 37°C and subjected to DELFIA assay. (a) Total binding (red) 
was determined in ER-positive cells and non-specific binding (black) was determined in ER-negative cells. Specific binding (blue) was calculated by subtracting 
non-specific from total binding. (B) Saturation-binding curve. Data points of specific binding were fitted to one-site binding equation yielding Kd = 0.56 μM, 
BMAX = 60.9 pmole, and R2 = 0.97. Data of OD scale were converted to molar units by comparing to OD values of known EPTA-Eu concentrations.
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cells, KaEPTA-Eu of 1.75 ± 0.2 μM and maximal-binding capacity 
Bmax = 3.53 ± 0.17 pmole per 106 cells (n = 3).
hormonal-induced Bioactivities of  
ePTa-gd and TPTa-gd in human Breast 
cancer cells
The protein level of ERα in the various human breast cancer cells 
examined in this study were determined by western blotting, cali-
brating the levels using a calibration curve of commercial hERα 
protein (Figure 4). The level of ER in the estrogen responsive cells 
T47D and MCF7 was 1,802 ± 842 and 10,377 ± 1,044 fmol/mg 
protein, respectively. The WT MDA-MB-231 cells had a null level, 
and the ER-transfected MDA-MB-231 cells had a high level of 
14,800 ±  980  fmol/mg protein. The expression levels in T47D, 
MCF7, and WT MDA-MB231 cells are in accord with previously 
published values for these cells (20, 23, 24).
Both EPTA-Gd and TPTA-Gd stimulated the proliferation of 
T47D and MCF7 cells in a dose- and time-dependent manner, but 
did not affect the proliferation rate of ER-negative MDA-MB-231 
cells (Figure  5). Statistical analysis of the proliferation rate of 
MCF7 and T47D cells induced by 1–2 μM EPTA-Gd showed a 
reproducible and significant stimulation of approximately two-
fold (p < 0.02, n = 5, two-tail paired t-test).
Unlike tamoxifen, competition of TPTA-Gd with E2 did not 
affect the proliferation of T47D and MCF7 cells (p > 0.3, two-
tailed paired t-test, n = 7). Thus, both ER-targeted probes exerted 
mild agonistic effect on the proliferation of estrogen responsive 
cells and were neither cytotoxic nor cytostatic to these cells.
The ability of the two targeted probes to regulate specific 
estrogen-induced molecular changes was investigated in MCF7 
cells. EPTA-Gd treatment induced a marked effect on cMyc and 
ERα expression level upregulating the level of cMyc by ~250% 
within 2 h and reducing ER level to 25% of its initial value at 4 h. 
Figure 6A shows the time course of the changes in cMyc and ERα 
expression induced by EPTA-Gd, obtained from two independ-
ent experiments. This time course is very similar to that reported 
for 17β-estradiol in the same type of cells (21). TPTA-Gd showed 
less pronounced effects than EPTA-Gd, yet cMyc expression 
increased to ~150% of its initial level and ER level decreased to 
60% of its initial level (Figure 6B, two independent experiments). 
These specific induced activities demonstrated the agonistic 
activity of EPTA-Gd and TPTA-Gd in a mechanism similar to 
17β-estradiol.
In Vivo interaction with er
The in vivo interaction of EPTA-Gd and TPTA-Gd with ER was 
investigated in orthotopic breast cancer xenografts of ER-positive 
FigUre 6 | changes in the expression level of erα (left) and cMyc 
(right) in McF7 cells induced by ePTa-gd (a) and TPTa-gd (B) at a 
concentration of 5 μM. In each panel, a representative blot is at the upper 
raw and the α-tubulin for normalization is at the bottom raw. The curve 
shows the fold change in expression levels, n = 2.
FigUre 5 | effect of ePTa-gd and TPTa-gd on the proliferation rates 
of human breast cancer cells. (a) Dose-dependent effect of EPTA-Gd on 
the proliferation rate of ER-positive T47D human breast cancer cells. (B) 
Dose-dependent effect of TPTA-Gd and of TPTA-Gd + E2 on the proliferation 
rate of ER-positive MCF7 human breast cancer cells. (c) Dose-dependent 
effect of EPTA-Gd on the proliferation rate of ER-negative WT MDA-MB-231 
human breast cancer cells. Cell proliferation was measured by the cell viability 
MTT assay, and each data point represents mean ± SD of six-replicate wells. 
Control: cells cultivated in E2-free medium.
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and ER-negative cells implanted in the same SCID mouse and 
were partly described in earlier publications (17, 18). Solid 
palpable tumors developed within a week after the implantation 
of cells into the mammary fat pad of the SCID mice. Both the 
ER-positive and ER-negative xenografts grew at a similar rate 
with no significant difference in their volume size during 22 days 
of growth (n = 10, paired t-test: p ≥ 0.9 in days 8, 11, 16, 18, and 
22 after implantation of the cells), reaching at 22 days a mean size 
of 220 ± 65 mm3.
Immunostaining of the ER-positive xenografts showed 
high nuclear ER staining in viable regions, whereas in the 
ER-negative xenografts the staining was very low (Figure  7A). 
Quantitative analysis showed that the percentage of ER-stained 
cells in the ER-positive xenografts was more than 10-fold higher 
(71.0  ±  0.05%, n  =  11) than in the ER-negative xenografts 
(2.12 ± 0.01%, n = 11). Similarly, the specific intensity index in 
the ER-positive xenografts was 10-fold higher (2.12 ± 0.01) than 
in the ER-negative xenografts (0.02 ± 0.08).
Administration of EPTA-Gd and TPTA-Gd into the blood 
circulation caused enhancement of the water signal with different 
FigUre 7 | immunohistology staining of erα (a) and Mri signal enhancement patterns induced by ePTa-gd (B,D) and by TPTa-gd (c,e) in 
er-positive and er-negative MDa-MB-231 human breast cancer xenografts. The injected dose of EPTA-Gd and TPTA-Gd was 0.075 mmol/kg. The curves 
in (B,D) show mean ± SD of EPTA-Gd-induced enhancement (n = 5). The curves in (c,e) show mean ± SD of TPTA-Gd-induced enhancement (n = 4).
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kinetic profiles for the ER-positive and ER-negative tumors, 
as shown in the time courses of the mean ±  SD enhancement 
curves in Figures 7B–E. The EPTA-Gd enhancement profile in 
the tumors indicated fast wash-in followed by a plateau, with the 
enhancement in the ER-positive xenografts (reaching 43 ± 20% at 
40 min postinjection) significantly higher than in the ER-negative 
xenografts (reaching 25 ± 5% at 40 min postinjection; p = 0.005, 
n =  9). In contrast, TPTA-Gd caused a low enhancement of 
13 ±  2% at 40  min postinjection, which did not differ signifi-
cantly from the enhancement in the ER-negative cells (p = 0.21, 
n = 4). As a reference to ER-negative tissue, we also monitored 
the enhancement induced by each agent in muscle tissues 
(Figure 8). The enhancement induced by EPTA-Gd in the muscle 
was low 15 ± 3% at 40 min postinjection (n = 9), with a wash-in 
followed by a marked washout phase (Figure 8C). In contrast, 
TPTA-Gd induced an appreciable enhancement in the muscle 
tissue (28 ± 5% at 40 min postinjection, n = 4), with no washout 
during the 140 min of the entire experiment (Figure 8D). These 
results indicated that the enhancement induced by EPTA-Gd in 
ER-positive tumors is significantly higher than in ER-negative 
tumors and in muscle tissue, however, TPTA-Gd exhibited 
similar and low enhancement in ER-positive and negative tumors 
and a specific interaction with muscle component(s). Since the 
PTA-part is identical in both EPTA-Gd and TPTA-Gd, the 
accumulation of TPTA-Gd in the muscle is most likely due to the 
interaction of a muscle component with the tamoxifen moiety.
competition studies of ePTa-gd with 
Tamoxifen
Investigation of the time course and extent of EPTA-Gd-induced 
enhancement showed that shortly after tamoxifen treatment 
(1 h), a similar enhancement of ~30% at 40 min postinjection was 
FigUre 8 | enhancement maps in muscle tissue 20 min after bolus injection of ePTa-gd (a) and TPTa-gd (B) into the tail vein of the mice and 
mean ± sD enhancement curves induced by ePTa-gd [(c), n = 5] and TPTa-gd [(D), n = 4]. The injected dose of EPTA-Gd and TPTA-Gd was 0.075 mmol/
kg. The enhancement maps are overlaid on the corresponding T1-weighted images.
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detected in ER-positive and ER-negative xenografts (p =  0.93, 
n = 4), as well as in muscle tissue (p = 0.43, n = 4) (Figures 9A,C). 
These results confirmed the binding of tamoxifen to ER and 
complete blocking of the interaction of EPTA-Gd to the ER.
Chronic treatment with tamoxifen for 3 days also caused the 
enhancement to be similar in ER-positive and ER-negative xeno-
grafts (p = 0.36, n = 4), confirming tamoxifen blockage of ER and 
inhibition of EPTA-Gd binding. However, the extent of maximum 
enhancement in the chronic treated xenografts was significantly 
higher (77 ± 16%) than that reached after acute, 1 h treatment 
with tamoxifen (28 ± 7%; p = 0.003, n = 4) (Figures 9B,D). This 
unexpected result indicated an effect of tamoxifen chronic treat-
ment on tumors’ vascular function, increasing the microvascular 
transcapillary transfer rates in both ER-positive and ER-negative 
tumors by an hormonal independent mechanism.
DiscUssiOn
The ER is a major prognostic biomarker in breast cancer and a 
valuable predictor of response to hormonal therapy. New molec-
ular imaging techniques that will enable to detect ER presence 
and distribution in vivo, in both primary and metastatic cancer 
lesions, could improve accuracy and reproducibility of prognostic 
assessment and therapy management of breast cancer patients. 
In this study, we describe the interactions, biological activity, and 
imaging efficiency of two new paramagnetic ER-targeted CAs in 
human breast cancer cells and human breast cancer xenografts.
We first measured the ER binding of EPTA-Gd and TPTA-Gd 
in solution and then monitored the interaction of these probes 
with ER in human breast cancer cells. In solution, despite the 
bulky organometallic moiety at the 17α-position of 17β-estradiol 
or trans 4-position of tamoxifen (occupied by an hydroxyl group 
in 4-hydroxy tamoxifen), the binding affinity to the receptor was 
at the micromolar range, as was also shown previously for other 
organometallic-labeled estradiol derivatives (25–27). Although 
the affinity of both ER-targeted probes was two orders of magni-
tude lower than that of tamoxifen, it appeared to be sufficiently 
high for interacting and binding to ER in breast cancer cells and 
xenografts using micromolar concentrations. The MRI relaxation 
studies and fluorescence binding confirmed the binding inside 
the cells, most likely to nuclear ER. MRI T1-relaxation studies 
in ER-positive and negative cells of the same origin showed 
augmentation of the T1-relaxation rate and the T1 relaxivity in 
the ER-positive cells as compared to ER-negative cells, indicat-
ing entrance to the cells and nuclei and binding to the receptor. 
Measurements of T1 and T2 in breast cancer cells perfused with 
medium containing varying concentrations of the ER-targeted 
probes further confirmed interaction with ER. Generally, 
Gadolinium-based CAs will affect both T1- and T2-relaxation 
rates. However, in in vivo studies of DCE MRI, due to time limita-
tions, gradient-echo relaxation weighted sequences are applied. 
The effect of the CA on the signal intensity in T1-weighted images 
is positive, namely, increase in signal, whereas in T2-weighted 
images it is negative, namely, signal reduction. An increase in the 
signal intensity can be detected more efficiently and accurately 
than the decrease in a T2-weighted image, particularly for a CA 
that is diffusing into the tissue and when the pre-contrast signal 
to noise ratio is low, as usually is the situation in vivo. Therefore, 
we predominantly concentrated on T1 measurements using a 
gradient-echo T1-weighted sequence in the in vivo studies.
Fluorescence-binding studies of the analogous paramagnetic 
agent EPTA-Eu provided a direct measure of the binding affinity 
in ER-positive cells and confirmed the capability of this agent to 
enter the cells and to bind to ER as in solution, with a micromolar-
binding affinity. It should be noted that relaxation and fluorescence 
studies in ER-negative cells indicated the presence of non-specific 
FigUre 9 | ePTa-gd induced enhancement patterns (a,B) and enhancement maps at 40 min (c,D) in er-positive and er-negative MDa-MB-231 
xenografts treated with acute (1 h) and chronic (3 days) tamoxifen. The anatomy of the xengorafts is demonstrated in the T2-weighted images (c,D). The 
enhancement maps are overlaid on the corresponding T1-weighted images.
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interactions with cell components, but these interactions did not 
mask the binding and interaction in the ER-positive cells. The ER 
non-specific interactions of TPTA-Gd appeared to be higher than 
those of EPTA-Gd, making this agent less favorable as a targeted 
probe. It was not possible to predict in advance whether the bind-
ing of the new probes to ER in cells will modulate gene expression 
in a similar manner to that of 17β-estradiol or of tamoxifen. It was 
expected that the 17β-estradiol moiety of EPTA-Gd will induce 
agonistic activity upon binding to ER, whereas the tamoxifen 
moiety may exhibit antagonistic activity like tamoxifen. Testing 
the SERM activity of EPTA-Gd and TPTA-Gd was therefore 
performed in well-established ER responsive human breast can-
cer cell lines, MCF7 and T47D, in reference to the ER-negative 
MDA-MB-231 human breast cancer cells. We have investigated 
typical estrogen-modulated processes that are known to be inhib-
ited by tamoxifen, such as cell proliferation, the expression level 
of cMyc, and the ER-expression level [Ref. (28–31) and references 
cited therein]. EPTA-Gd and TPTA-Gd exhibited estrogen-like 
agonistic effects, with EPTA-Gd mimicking closely estradiol 
activity and TPTA-Gd showing mild agonistic effects. Both new 
agents stimulated cell proliferation at a dose-dependent manner. 
This stimulation was specific to the presence of ER in the cells, as 
there was no effect on the growth of ER-negative MDA-MB-231 
human breast cancer cells. They also induced the upregulation 
of cMyc and downregulation of ER, due to ER-enhanced deg-
radation. The ability of these two new agents to induced typical 
estrogen-like activities clearly indicated their capability to enter 
the cells and nuclei and interact with the receptor to trigger 
specific estrogen-mediated responses. Furthermore, the E2-like 
activities demonstrated that the conjugated pyridine–Gd com-
plex of EPTA-Gd did not alter the function of the 17β-estradiol 
moiety in inducing estrogenic agonistic-like activity on breast 
cancer cell, whereas the conjugated pyridine–Gd complex in 
TPTA-Gd modified the antagonistic function of the tamoxifen 
moiety yielding a mild agonistic activity.
The ability of EPTA-Gd to act agonistically was strongly sup-
ported by the X-ray crystalographic structure of the complex of 
EPTA-Eu with the ligand-binding domain of ER (19). Because of 
the chirality of C17 in the 17β-estradiol moiety and due to the rigid 
triple bond linking it with the PTA-Eu moiety, the orientation 
of the organometallic moiety is fixed within the ligand-binding 
cavity, being almost perpendicular to the flat face of 17β-estradiol 
and pointing toward helix 7 in an opposite direction to helix 12. 
Consequently, the conformation of the 17β-estradiol moiety of 
EPTA-Gd in the ER-binding cavity is almost equivalent to that of 
free 17β-estradiol and the paramagnetic PTA-Gd moiety causes 
uncoiling of helices 7 and 8, but does not perturb the agonistic 
activity determined by helix 12 conformation.
As TPTA-Gd is based on a tamoxifen moiety, it was not clear 
which conformation it will adopt in the ER-binding cavity and how 
it will modulate the activity. If the 4-[2 -(dimethyl amino) ethoxy] 
group of the tamoxifen moiety would have been aligned in the 
ligand-binding cavity as tamoxifen, it could change helix 12 con-
formation in a similar manner to the change induced by 4-hydroxy 
tamoxifen (32), leading to antiestrogen activity. However, the rigid 
triple bond in the 4-position and the flexibility of tamoxifen struc-
ture could lead to an enlargement and distortion of the binding 
cavity in a similar way to that obtained with EPTA-Gd directing 
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the PTA-Gd moiety toward helices 7 and 8 and accommodating 
the dimethylamino ethoxy group in a conformation, which does 
not perturb significantly helix 12 conformation. This hypothesis is 
in accord with recent X-ray studies suggesting that the flexibility 
and plasticity of the entire ligand-binding cavity of ER allows 
expanding of the cavity space in different directions, depending on 
the chemical nature of the bound ligand (33–35). The well-defined 
structure by X-ray crystallography provides direct evidence on the 
ability of a ligand to interact with ER in the solid state and induce 
agonistic or antagonistic activity. However, it should be noted that 
conformational changes of ER in the tissue environment, specifi-
cally in the nucleus, may alter the interaction between the ligand 
and the receptor and modify the induced activity.
The main purpose of the in vivo studies was to evaluate the 
ability of the two ER-targeted CAs to demonstrate augmented 
enhancement upon binding to ER, thereby detecting ER-positive 
tumors. Indeed, EPTA-Gd interacted with ER as expected from 
the cell culture studies and specifically augmented significantly 
the MRI signal in the ER-positive xenografts as compared to 
the ER-negative xenografts and to muscle tissue. The muscle 
enhancement was low and also decayed after ~20 min as expected 
for molecules that do not show specific interaction with extracel-
lular or intracellular components and are cleared out through the 
kidneys (17). Furthermore, the inability of EPTA-Gd to induce 
enhancement when ER was blocked by tamoxifen served to 
prove its selective binding to free ER. In contrast, the interac-
tion and enhancement patterns induced by TPTA-Gd could not 
be predicted from the breast cancer cell culture studies, as this 
probe strongly enhanced in vivo muscle tissues, demonstrating a 
dominant non-ER-specific binding to muscle components. This 
non-specific interaction is most likely determined by the tamox-
ifen moiety as the paramagnetic moiety is the same in EPTA-Gd 
and TPTA-Gd. It was previously shown that in addition to its 
high-affinity binding to the ER, tamoxifen binds with high affin-
ity to microsomal antiestrogen-binding site (AEBS) and inhibits 
with a micromolar efficiency, protein kinase C (PKC), calmodulin 
(CaM)-dependent enzymes, and Acyl coenzyme A: cholesterol 
acyltransferase (ACAT) (36–38).
An additional ER-independent effect of tamoxifen was 
revealed in the competition studies of EPTA-Gd and tamoxifen. 
Acute tamoxifen treatment for 1  h did not affect the vascular 
function of the ER-positive and negative xenografts. However, 
chronic treatment for 3 days caused in both types of xenografts 
a higher transcapillary transfer and augmented enhancement 
suggesting specific tamoxifen-induced interaction with tumor 
endothelial cells that change the vascular permeability. It was 
previously demonstrated that chronic tamoxifen treatment for 
several days increased the transcapillary transfer of MCF7 xeno-
grafts in nude mice (39). It was also shown by Blackwell et al. (40) 
that tamoxifen exerts significant inhibition of angiogenesis in an 
ER-independent mechanism. The effects on the vascular function 
during chronic treatment with tamoxifen could be indirect, such 
as increased hypoxia and consequently upregulation of VEGF 
expression level, but we cannot exclude direct interaction with 
endothelial cells.
Of specific interest was the effect of EPTA-Gd on ER level. 
The amount of ER in cells is controlled by a balance between its 
synthesis and degradation and is influenced by the nature of the 
bound ligand. Like estrogen treatment (21), EPTA-Gd induced a 
marked decrease in ER within few hours, which slowly returned 
to steady state level at 48 h posttreatment. This temporal change 
in ER level are directly associated with the functional response 
of ER and reflects estrogen responsiveness in general. Further 
studies are required for extending the use of EPTA-Gd to moni-
tor temporal changes in ER level and characterize ER functional 
activity. Moreover, it was recently indicated that the shape of an 
estrogenic ligand programs the conformation of the ER complex, 
which, in turn, can modulate the activity of estrogen-induced 
apoptosis (41). The mechanism of estrogen-induced apoptosis 
has been associated with the positive response to treatment 
with estradiol, or with partial ER agonists of ER-positive breast 
cancers resistant to long-term estrogen deprivation (for example, 
by tamoxifen) (42, 43).
The ability of partial ER agonists to induce apoptosis in 
ER-positive cells suggests that the clinical application of 
EPTA-Gd may not cause any harm to breast cancer patients 
with ER-positive tumors and could even be effective by inducing 
apoptosis. Further studies investigating whether EPTA-Gd can 
induce apoptosis may lead to its development as a dual-targeted 
ER probe for imaging and treatment, particularly of tamoxifen-
resistant ER-positive cancers. Clearly, although EPTA-Gd was 
found to be non-toxic to mice, at the doses administered in this 
study, and to be cleared out into the urine, any future clinical 
utilization will require controlled toxicity studies in humans. 
Thus far, new MRI probes targeted to the progesterone receptor 
were also synthesized, demonstrating specific enhancement in 
progesterone  –  positive cancer cells and animal model tumors 
(44–47). Currently, however, the only imaging approach for visual 
assessment and quantitative measurement of steroid hormone 
receptors in humans have focused predominately on 18F-based 
radiopharmaceuticals and PET, in combination with computed 
tomography (48).
In summary, EPTA-Gd and TPTA-Gd were found to act as 
SERMs with partial agonistic activities, inducing proliferation of 
estrogen responsive cells and modulating gene expression levels 
of ER and cMyc. Both agents entered the cells and augmenting the 
T1-relaxation rate of the water in their surrounding through bind-
ing to ER. However, only EPTA-Gd was found to be an adequate 
ER-targeted probe in  vivo as TPTA-Gd exhibited non-specific 
interaction with cell components other than ER, particularly in 
muscle tissue, that dominated its ability to induce MRI contrast 
in ER-positive tumors.
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